2型糖尿病患者接受GLP-1受体激动剂治疗后的强化策略与代谢结局
基于AMD Annals数据库的回顾性队列研究,纳入2010至2022年间191041例使用GLP-1受体激动剂(GLP-1 RA)的2型糖尿病(T2D)患者,其中37198例接受首次治疗强化。加用口服降糖药(OAD)或基础胰岛素(BI)/固定比例复方制剂(FRC)是兼顾血糖控制与避免体重增加的强化策略,而换用BI者达标率低且存在治疗惰性。
要点
- 加用OAD或BI/FRC可在避免体重增加的同时改善血糖控制。
- 换用BI者HbA1c<7%达标率仅16.8%,且体重增加2.9 kg。
- 所有强化策略均存在胰岛素滴定不充分。
核心结论
- 在GLP-1 RA基础上加用OAD或BI/FRC是兼顾血糖控制与避免体重增加的最佳强化策略。
- 换用胰岛素治疗的患者达标率低,治疗惰性仍是临床实践中的关键问题。
研究设计与样本
- 回顾性队列研究,基于AMD Annals数据库,从2010至2022年间191041例使用GLP-1 RA的患者中筛选出37198例接受首次治疗强化的T2D患者。
- 按强化策略分层,比较基线特征及6个月和12个月时的HbA1c与体重变化。
主要发现
- 多数强化患者接受OAD,尤其是体重指数较高、HbA1c较低和病程较短者。
- BI主要用于HbA1c较高(8.9%)和糖尿病病程较长者。
- BI或换用FRC的HbA1c降幅最大(分别为-0.92%和-0.85%;P<.001),且体重中性。
- OAD的达标率更高(HbA1c<7%者为36%),并持续减重。
- 换用BB者体重增加(+2.9 kg;P<.001),达标率较低(HbA1c<7%者为16.8%)。
关键数值与推荐
- BI组HbA1c降幅-0.92%,FRC组-0.85%(P<.001)。
- OAD组HbA1c<7%达标率36%。
- 换用BB组体重增加+2.9 kg(P<.001),HbA1c<7%达标率16.8%。
临床怎么用
- 作者认为,在GLP-1 RA基础上加用OAD或BI/FRC是兼顾血糖控制与避免体重增加的最佳强化策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), many patients with type 2 diabetes (T2D) require additional therapy to achieve glycated hemoglobin (HbA1c) targets. Few studies have explored real-world outcomes following GLP-1 RA failure. OBJECTIVE: This analysis evaluates different intensification approaches, timing, and outcomes in patients with T2D on GLP-1 RAs. METHODS: This retrospective cohort study was based on the AMD Annals database. From 191 041 patients on GLP-1 RAs between 2010 and 2022, individuals receiving a first therapeutic intensification were selected. Patients were stratified by intensification strategy; baseline characteristics were compared alongside HbA1c and weight changes at 6 and 12 months. RESULTS: Among the 37 198 intensified patients, the majority received oral antihyperglycemic drugs (OADs), particularly those with higher body mass index, lower HbA1c, and shorter disease duration. Basal insulin (BI) was mainly added in those with higher HbA1c (8.9%) and longer diabetes. Intensification with BI or switch to fixed ratio combinations (FRCs) yielded the greatest HbA1c reduction (-0.92 and -0.85%; P < .001) and weight neutrality, whereas OADs led to a higher target achievement rate (36% with HbA1c < 7%) and persistent weight loss. Switching to BB was reserved for more complicated patients and it was associated with weight gain (+2.9 kg; P < .001) and lower target achievement rate (16.8% HbA1c < 7%). Suboptimal insulin titration was observed across all strategies. CONCLUSION: Adding OADs or BI/FRCs to GLP-1 RAs are optimal intensification strategies to provide glycemic control while avoiding weight gain. Target achievement rates are poor in individuals switched to insulin therapy. Therapeutic inertia remains a critical issue in clinical practice.
引用
- Falcetta P, Zilich R, Baccetti F, et al. Treatment Intensification Strategies and Metabolic Outcomes in Individuals With Type 2 Diabetes on GLP-1 RA Therapy. J Clin Endocrinol Metab. 2025. PMID: 40199481. doi:10.1210/clinem/dgaf229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。